

## Thursday 15/03/2018

### 11.00-12.30 Round Table: Principles in diagnosis of NET Tumors

Chairs: Ch. Toumpanakis (UK), A. Koumarianou (GR)

Molecular heterogeneity  
Emerging Data on Epidemiology and Risk Factors  
Novel pathologic classification  
Endoscopic diagnostic and therapeutic procedures in NETs

M. Milione (IT)  
G. Kaltsas (GR)  
K. Papaparaskeva (GR)  
Ch. Toumpanakis (UK)

### 12.30-14.00 Round Table: Therapeutic Advances in NETs

Chairs: G. Kaltsas (GR), M. Tzardi (GR)

Treatment Landscape of NETs. Current clinical practice  
The emerging role of Peptide Receptor Radionuclide Therapy  
Combined Medical Therapeutics  
Emerging therapeutics/targeted drugs

A. Angelousi (GR)  
S. Hatzioannou (GR)  
A. Koumarianou (GR)  
L. Chatzelis (GR)

### 14.00-15.00 Lunch

### 15.00-16.00 Round Table: Therapeutic Principles in GISTs

Chairs: I. Boukovinas (GR), S. Gavriel (GR)

Laparoscopic Surgery and challenging scenarios in early disease (invasion of margins, detection of micrometastatic disease during surgery, intraperitoneal rupture, other)  
Adjuvant Therapy: When and How  
Emerging Therapies in GIST

K. Tepetes (GR)  
H. Duran Moreno (GR)  
S. Kokkali (GR)

### 16.00-17.30 Round table: Liver Cancer (I)

Chairs: O. Katopodis, A. Roussakis (GR)

An OncoBridge Project: The epidemiological characteristics of HCC patients in Near Eastern countries  
The impact of new antiviral therapies for HCV on the occurrence and recurrence of HCC  
Diagnostic modalities for defining resectability (CT, EUS, MRI, PET)  
Stage-dependant management of HCC/systemic treatment

N. Turhal (TU)  
S. Dourakis (GR)  
Ch. Triantopoulou (GR)  
D. Tzannis (GR)

### 17.30 – 18.00 Coffee Break

### 18.00-19.00 Round table: Biliary tumors (II)

Chairs: P. Kountourakis (CY), G. Chalkiadakis (GR)

Local therapies for hepatobiliary tumors  
Systemic treatment in cholangiocarcinoma  
Immunotherapy for hepatobiliary tumors

A. Chatzioannou (GR)  
G. Papaxoinis (GR)  
N. Pistamaltzian (GR)

### 19.00-19.30 Chairs: I. Boukovinas (GR), D. Hatzibougias (GR)

Invited Lecture : "Arguments for the introduction of an «I» for Immune in the TNM classification" J. Galon (FR)



# Advances and Perspectives in Gastrointestinal Oncology

15-17 March 2018  
Crowne Plaza Hotel | Athens | Greece



## 19.30-20.30 Lectures

Chairs: Gr. Kouraklis (GR), A. Chatziioannou (GR)

The role of liver transplantation in hepatobiliary tumors  
The role of SIRT in GI tumors

A. Prachalias (UK)  
A. Karampezis (GR)

**Friday 16/03/2018**

## 08.30-10.00 Round table: Pancreas (I)

Chairs: A. Polydorou (GR), A. Prachalias (UK), D. Kypreos (GR)

Optimal screening for pancreatic cancer  
The hereditary nature of pancreatic cancer  
Therapeutic endoscopic approaches to pancreatobiliary tumors  
Management of Marginally Resectable Pancreatic Cancer

N. Kentepozidis (GR)  
E. Saloustros (GR)  
A. Vezakis (GR)  
M. Konstantoulakis (GR)

## 10.00-10.30 Coffee break

## 10.30-11.30 Round Table: Pancreas (II)

Chairs: M. Tolia (GR), Th. Makatsoris (GR)

Adjuvant Radiotherapy in pancreatic cancer  
Stereotactic radiosurgery in the upper abdomen  
Neoadjuvant and adjuvant systemic treatments in pancreatic cancer

H. H. Saraireh (JOR)  
G. Filippou  
O. Katopodis (GR)

## 11.30-12.30 Lectures

Chairs: G. Zografos (GR), H.H. Saraireh (JOR)

Minimally invasive surgical management of pancreahepatotobiliary malignancies  
Systemic treatment for metastatic Pancreatic Cancer. Why are we failing to effectively target this disease

A. Petrou (CY)  
I. Athanasiadis (GR)

## 12.30-14.00 Gastric/Oesophagus: Recent advances-State of the art (I)

Chairs: T. Liakakos (GR), Ch. Kosmas (GR)

Barrett's Esophagus and Early cancer Management  
Genetic syndromes associated with increased risk of gastroduodenal cancer  
The role of EBV to better classify, treat and monitor gastric cancer  
Diagnostic approach of early gastric cancer

D. Theodorou (GR)  
G. Lypas (GR)  
D. Repana (UK)  
G. Karamanolis (GR)

## 14.00-15.00 Lunch



## 15.00-16.00 Debate: Perioperative chemotherapy vs Chemo/RT in GEJ adenocarcinoma

Chairs: Ch. Papadimitriou, V. Michalaki (GR)

Pro (chemo only)  
Con

P. Kountourakis (CY)  
Th. Makatsoris (GR)

## 16.00-16.30 Coffee break

## 16.30-18.00 Round table: Gastric/Oesophagus: Treatment advances (II)

Chairs: A. Machairas (GR), N.Xiros (GR)

Neoadjuvant and adjuvant treatment in Gastric/GEJ  
The current treatment algorithm for the inoperable or metastatic gastric cancer  
Lymph node regression following chemotherapy for oesophageal cancer  
Immunotherapy in gastroesophageal cancer

A. Strimpakos (GR)  
P. Kountourakis (CY)  
A. Davies (UK)  
A. Kotsakis (GR)

## 18.00-19.00 Lectures: Gastric/GEJ (iii)

Chairs: D. Theodorou (GR), A. Davies (UK)

Management of esophageal adenocarcinomas after neoadjuvant therapy with complete clinical response-Surgery vs watchful waiting  
Positive peritoneal cytology with no macroscopic metastatic disease in laparoscopic staging of patients with Gastric/GEJ adenocarcinoma. Are these cases never operable?

N. Charalampakis (GR)  
A. Tentis (GR)

## 19.00-20.30 The future of GI Oncology

Chairs: V. Georgoulas (GR), Ch.Papadimitriou (GR)

The surgeon of the future  
The GI endoscopist in the future  
The radiation oncologist of the future  
The pathologist of the future  
The radiologist in the future

N. Nikiteas (GR)  
J. Papanikolaou  
M. Koukourakis (GR)  
G. Koukoulis (GR)  
P. Prassopoulos (GR)

**Saturday 17/03/2018**

## 10.00-11.30 Round Table: Colorectal cancer (I)

Chairs: G. Pentheroudakis (GR), K. Papadimitriou (BE)

The oncogenesis/heterogeneity of CRC  
CMS / molecular classification of CRC. Ready for prime time in the management of mCRC?  
Liquid biopsy in the management of mCRC. The future is now?  
Colon cancer adjuvant therapy: 3 vs 6 months. Clinical practice implications.

G. Papaxoinis (GR)  
P. Foukas, A. Spathis (GR)  
D. Diamantidis (US)  
I. Boukovinas (GR)



**11.30-12.00** Coffee Break

**12.00-13.30** Round table: Treatment challenges in rectal cancer (II)

Chairs: T. Theodosopoulos (GR), A. Dimopoulos (GR), M. Christodoulakis (GR)

Early rectal cancer: which technique and from whom  
Laparoscopic vs total mesorectal excision  
Optimal management of localized rectal cancer  
Defining the strategy in oligometastatic rectal cancer

G. Theodoropoulos (GR)  
E. Chrysos (GR)  
R. Glynne Jones (UK)  
E. Antoniou (GR)

**13.30-15.00** Lunch

**15.00-16.30** Lectures

Chairs: D. Papamichael (CY), D. Diamantidis (US)

Treatment of metastatic colorectal cancer beyond first line  
Treatment options for BRAF mutated mCRC  
Immunotherapy in CRC beyond MSI. Future prospects  
Malignant appendix-peritoneal pseudomyxoma: how to handle

Ch. Emmanouilidis (GR)  
K. Papadimitriou (BE)  
P. Papanastopoulos (CY)  
I. Kontis (GR)

**16.30-17.30** Round table: Colorectal cancer (III)

Chairs: G. Fragoulidis (GR), E. Petinellis (GR)

Management of rectal cancer with synchronous liver metastases (to discuss optimal therapeutic sequence and timing of surgery for primary and metastatic disease)  
Surgeon  
Medical oncologist  
Radiotherapist

E. Felekouras (GR)  
D. Papamichael (CY)  
M. Trichas (GR)

**17.30-18.00** Coffee break

**18.00-19.00** Lectures

Chairs: G. Polymeneas (GR), Ch. Papadimitriou (GR)

Management of patients with rare molecular alterations  
Surgical management of cancers in patients with a genetic predisposition

A. Diglia (CH)  
M. Pramateftakis (GR)

**19.00** Closing Remarks

